-
Most Popular
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
The Top Performing Sector in 2020 Will Be …
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.
Amarin Stock is Still Fully Valued Despite All the Good News
AMRN stock is likely fairly priced -- possibly even overpriced -- right now. It might take more time before analysts and the company actually raise their revenue and cash flow estimates based on patient uptake of Vascepa.
Buffett Owns Teva Stock, But Should You?
Teva stock has been a long-term loser, but there are signs that things are starting to turn around. Should investors consider it in 2020?
Why We Had to Add This Stock to Our 2020 “Screaming Buy” List
Our research and analysis have identified another name in biotech stocks with big potential in 2020.
Embattled TEVA Has Made Headlines for All of the Wrong Reasons
Teva Pharmaceuticals is under the glare of legal and regulatory scrutiny. However, TEVA will eventually find its way because frankly, it has to.
Amarin Stock is at Sky-High Levels Already Assumes All the Good News
Amarin stock is at sky high levels assuming all the good news. The FDA drug approval was anticipated and the AMRN stock price had implied it already.
Why Longer-Term Investors Should Buy Amarin Stock on Weakness
Short sellers have targeted AMRN and the Amarin stock price is quite undervalued, making the shares quite attractive for long-term investors.
Collect on the Pharmaceutical Boom With Eli Lilly
Eli Lilly and Company (NYSE:LLY) provided optimistic guidance for 2020 today, and it looks like the stock will head higher at the open this morning.
You Can’t Afford to Miss This Buying Opportunity
There's a catalyst on the horizon that could send biotech stocks soaring into the stratosphere.
The Most Overlooked Investment Theme Heading Into 2020
Chinese biotech stocks are set for not just 10X growth … not 20X growth … not even 50X growth … but at least 100X growth.
Amarin Stock’s Big Q4 Gains May Not Last as Big Dogs are Barking
Thanks to the effective cardiovascular drug Vascepa, Amarin stock has enjoyed an outsized performance so far this year. However, over the horizon stands big pharmaceutical competitors that are ready to spoil the party.
7 Catalysts Pointing to Massive Potential in Chinese Biotech Stocks
Even beyond China’s strong support of biotech, there are seven more reasons why investing in the sector will be one of the best wealth-building opportunities of the next 20 years.
Chinese Biotech Stocks: The 100X Play as Big Pharma Money Moves In
Investing in Chinese biotech stocks today is similar to getting into U.S. biotech back in the 1990s.
Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.
